LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

Inicio・Lista de Acciones・AbCellera Biologics Inc

AbCellera Biologics Inc

Cerrado

SectorSalud

3.73 1.08

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.61

Máximo

3.83

Métricas clave
By Trading Economics
Ingresos	-22M -57M
Ventas	-8.1M 9M
BPA	-0.19
Margen de beneficio	-637.845
Empleados	596
EBITDA	-1.4M -40M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+81.25% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-530M 1.1B
Apertura anterior	2.65
Cierre anterior	3.73

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.99 / 2.635 Soporte y Resistencia

AbCellera Biologics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

10 dic 2025, 22:02 UTC

Ganancias

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 dic 2025, 21:46 UTC

Ganancias

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 dic 2025, 23:52 UTC

Adquisiciones, fusiones, absorciones

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 dic 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 dic 2025, 23:36 UTC

Charlas de Mercado

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 dic 2025, 23:20 UTC

Ganancias

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 dic 2025, 23:15 UTC

Ganancias

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 dic 2025, 22:59 UTC

Charlas de Mercado

Ganancias

Adquisiciones, fusiones, absorciones

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 dic 2025, 22:45 UTC

Charlas de Mercado

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 dic 2025, 22:40 UTC

Ganancias

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dic 2025, 22:06 UTC

Adquisiciones, fusiones, absorciones

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dic 2025, 22:06 UTC

Ganancias

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dic 2025, 22:02 UTC

Ganancias

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dic 2025, 22:00 UTC

Ganancias

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 dic 2025, 21:53 UTC

Ganancias

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dic 2025, 21:50 UTC

Adquisiciones, fusiones, absorciones

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 dic 2025, 21:50 UTC

Charlas de Mercado

Ganancias

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

10 dic 2025, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

10 dic 2025, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

10 dic 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dic 2025, 21:33 UTC

Ganancias

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 dic 2025, 21:32 UTC

Ganancias

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dic 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 dic 2025, 21:25 UTC

Ganancias

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dic 2025, 21:18 UTC

Adquisiciones, fusiones, absorciones

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 dic 2025, 21:16 UTC

Ganancias

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 dic 2025, 21:15 UTC

Adquisiciones, fusiones, absorciones

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 dic 2025, 21:15 UTC

Ganancias

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 dic 2025, 21:14 UTC

Ganancias

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 dic 2025, 21:14 UTC

Ganancias

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Comparación entre iguales

Cambio de precio

AbCellera Biologics Inc Esperado

Precio Objetivo

By TipRanks

81.25% repunte

Estimación a 12 meses

Media 6.67 USD 81.25%

Máximo 9 USD

Mínimo 4 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbCellera Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para AbCellera Biologics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.99 / 2.635Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.